pharma news today obesity drugs glp-1 october 2025 Novo, Lilly weight-loss should be first option treatments, European doctors say Obesity GLP-1 Market

The results show that DPP-4 inhibition reduces HbA1c in these patients and that the treatment is well-tolerated with similar rate of adverse events as placebo

25 The bulk of the remaining 10% of the patients are diagnosed with type 1 diabetes (T1D), although other types exist that are rare

Pharmacogenomics on the treatment response in patients with psoriasis: an updated review

Ultrasonography of the brachial plexus, normal appearance and practical applications

In this review we will discuss the evidence which suggests renoprotection induced by GLP-1 receptor agonists and the potential mechanisms that may be involved